A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the ...

Intrathecal onasemnogene abeparvovec (OAV101 IT), an investigational, one-time gene replacement therapy, demonstrated a ...

Novartis (NYSE:NVS) said a Phase 3 study of an intrathecal formulation of its gene therapy Zolgensma, also known as OAV101 IT, met its primary endpoint in the treatment of children with spinal ...

Baclofen 50mcg/mL, 500mcg/mL, 2000mcg/mL; for intrathecal inj; preservative-free. <4yrs: not established. ≥4yrs: Give test dose 1 st by intrathecal inj via spinal catheter or lumbar puncture ...

An intravenous form of the gene therapy is already approved and sold as Zolgensma in the US for patients less than 2 years of age.

Novartis announces positive data from phase III study of intrathecal onasemnogene abeparvovec in broad patient population with SMA: Basel Friday, March 21, 2025, 11:00 Hrs [IST] N ...

Novartis NVS reported promising new safety and efficacy results from its phase III studies of investigational intrathecal ...

High-dose methotrexate (HD-MTX) with the modified Bonn protocol including intrathecal therapy is effective for patients less than 65 years old with primary central nervous system lymphoma (PCNSL), ...